ERASE: Esophagectomy Enhanced Recovery After Surgery Protocol

Sponsor
Raquel Ferrandis Comes (Other)
Overall Status
Recruiting
CT.gov ID
NCT04750096
Collaborator
(none)
100
1
28
3.6

Study Details

Study Description

Brief Summary

Despite the important advances in anaesthesia and the implementation of perioperative care, pulmonary complications in esophagectomy reach figures of between 20 and 35%, and these complications are also closely associated with the mortality rate. Factors that have been associated with the development of respiratory failure in the literature include among others the presence of previous respiratory pathology, history of smoking, malnutrition and rescue surgery.

With the aim of improving morbimortality in patients undergoing esophagectomy, a multidisciplinary protocol based on the best scientific evidence at the present time has been implemented, with actions covering both the preoperative and postoperative areas. Based on this point, a prospective study has been designed that allows us to compare the incidence of respiratory failure before and after the implementation of the protocol.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Esophageal carcinoma is the sixth leading cause of cancer death worldwide and the main treatment still remains oesophagectomy, a technique associated with a high morbidity and mortality rate. Despite the important advances in anaesthesia and the implementation of perioperative care, pulmonary complications in these patients reach figures of between 20 and 35%, and these complications are also closely associated with the mortality rate. Factors that have been associated with the development of respiratory failure in the literature include among others the presence of previous respiratory pathology, history of smoking, malnutrition and rescue surgery.

    With the aim of improving morbimortality in patients undergoing oesophagectomy, a multidisciplinary protocol based on the best scientific evidence at the present time has been implemented, with actions covering both the preoperative and postoperative areas. Based on this point, a prospective study has been designed that allows us to compare the incidence of respiratory failure before and after the implementation of the protocol.

    The secondary objectives are to analyse the changes produced in terms of morbimortality after the implementation of the protocol and the repercussion of these changes on the length of stay in the Resuscitation Unit.

    To carry out this project, data obtained in the first instance from patients operated before the implementation of the enhanced recovery after surgery protocol will be compared with data obtained prospectively after the implementation of the protocol.

    The data will be collected from the computerised and digitalised medical records of the patients on Orion Clinic® and Interspace intelligence Critical Care and Anesthesia, Philips ®. Patients operated on between 19 October 2020 and 19 October 2021 will be included consecutively. Prior to the operation, patients must sign an informed consent form to authorize the monitoring of their data during the first 30 days after the operation. These data will include:

    • Days of stay

    • Development or not of respiratory failure on initial admission, as well as the ventilatory therapy used (non-invasive and invasive) and days of mechanical ventilation

    • Fluid balance at 24 hours

    • Adequate completion of the protocol on a post-operative basis. The items of the protocol completed during the postoperative period will be detailed, taking into account the following points:

    1. Use of epidural analgesia

    2. Adequate pain control

    3. Realisation of neutral or negative balances

    4. Introduction of enteral nutrition by jejunostomy

    5. Performance of respiratory physiotherapy

    6. Use of high-flow nasal glasses with a minimum flow of 40 litres.

    7. Start of sedation on the second post-operative day

    8. Antithrombotic prophylaxis

    • The need or not for new drains and the reason for their installation will also be collected in order to evaluate the effectiveness of the transhiatal drains included in our protocol.

    Data regarding re-entry will be collected on

    • Reason for re-entry

    • Evolutionary day after surgery when readmission took place (day 1 being counted as the day of esophagectomy)

    • Days in the Critical Care Unit

    • Development or not of respiratory insufficiency, and in positive cases, requirement of invasive or non-invasive mechanical ventilation and days of therapy with it.

    Finally, the morbidity and mortality variables will be collected:
    • Respiratory complications: pleural effusion, atelectasis, pneumothorax, pneumonia, adult respiratory distress syndrome (ARDS).

    • The development of complications other than respiratory ones.

    • The need for reintervention and the underlying cause.

    • If exits occur, as well as the cause of death in hospital or in the first 30 days after surgery.

    The data will be analysed using Statistical Package for the Social Sciences software ® (version 12).

    Study Design

    Study Type:
    Observational
    Anticipated Enrollment :
    100 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Respiratory Failure in Esophagectomy. Results After Implantation of Enhanced Recovery After Surgery Protocol.
    Actual Study Start Date :
    Sep 1, 2020
    Anticipated Primary Completion Date :
    Sep 1, 2022
    Anticipated Study Completion Date :
    Dec 31, 2022

    Arms and Interventions

    Arm Intervention/Treatment
    Esophagectomy post enhanced recovery after surgery

    Patients undergoing esophagectomy due to oesophageal cancer under Enhanced Recovery After Surgery protocol.

    Outcome Measures

    Primary Outcome Measures

    1. Post-operative respiratory failure [1 month]

      Post-operative respiratory failure in esophagectomy after introduction of Enhanced Recovery After Surgery protocol

    Secondary Outcome Measures

    1. Other morbidity [1 month]

      Analyse changes in terms of morbidity and mortality different from respiratory failure following the implementation of the protocol. It will allow us to know the impact of the measures carried out on complications and mortality.

    2. Stay at ICU [1 month]

      Changes produced in the resuscitation stay after the Enhanced Recovery After Surgery protocol.

    3. Main predisposing factors [1 month]

      Main predisposing factors for the development of respiratory insufficiency.

    4. Respiratory failure as a prognostic factor [1 month]

      Analyse the presence of respiratory failure as a prognostic factor. This allows us to know the impact of respiratory failure on the evolution of the patient.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 90 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patients undergone esophagectomy due to neoplastic causes

    • Ages between 18 and 90

    • Programmed surgery

    Exclusion Criteria:
    • Caustic esophagitis

    • Esophagectomy for stomach cancer

    • Congenital oesophageal malformations

    • Respiratory failure at the time of surgery

    • Re-interventions of esophagectomy

    • Unexpected intraoperative surgical problems

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 La Fe University and Polytechnic Hospital Valencia Spain 46026

    Sponsors and Collaborators

    • Raquel Ferrandis Comes

    Investigators

    None specified.

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Raquel Ferrandis Comes, Doctor, Instituto de Investigacion Sanitaria La Fe
    ClinicalTrials.gov Identifier:
    NCT04750096
    Other Study ID Numbers:
    • ERASE 001
    First Posted:
    Feb 11, 2021
    Last Update Posted:
    Feb 11, 2021
    Last Verified:
    Feb 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Raquel Ferrandis Comes, Doctor, Instituto de Investigacion Sanitaria La Fe

    Study Results

    No Results Posted as of Feb 11, 2021